Lymph node metastasis, creatinine clearance rate of ≤60 mL per minute, RBC count of ≤3.3×1012 per liter, and combination therapy with vascular endothelial growth factor inhibitors are independent risk factors for PARPi SHAEs in patients with ovarian cancer. This evidence concerns the gene VEGFA and metastatic malignant neoplasm in the lymph nodes.